167 related articles for article (PubMed ID: 24370686)
1. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis.
Xu CP; Xue XJ; Liang N; Xu DG; Liu FJ; Yu XS; Zhang JD
J Cancer Res Clin Oncol; 2014 Apr; 140(4):549-59. PubMed ID: 24370686
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer.
Kim DW; Lee G; Hong TS; Li G; Horick NK; Roeland E; Keane FK; Eyler C; Drapek LC; Ryan DP; Allen JN; Berger D; Parikh AR; Mullen JT; Klempner SJ; Clark JW; Wo JY
Ann Surg Oncol; 2022 Jan; 29(1):242-252. PubMed ID: 34480285
[TBL] [Abstract][Full Text] [Related]
3. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Doppenberg D; van Dam JL; Han Y; Bonsing BA; Busch OR; Festen S; van der Harst E; de Hingh IH; Homs MYV; Kwon W; Lee M; Lips DJ; de Meijer VE; Molenaar IQ; Nuyttens JJ; Patijn GA; van Roessel S; van der Schelling GP; Suker M; Versteijne E; de Vos-Geelen J; Wilmink JW; van Eijck CHJ; van Tienhoven G; Jang JY; Besselink MG; Groot Koerkamp B;
Br J Surg; 2023 Sep; 110(10):1374-1380. PubMed ID: 37440421
[TBL] [Abstract][Full Text] [Related]
5. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.
Pan L; Fang J; Tong C; Chen M; Zhang B; Juengpanich S; Wang Y; Cai X
World J Surg Oncol; 2019 Dec; 18(1):1. PubMed ID: 31892339
[TBL] [Abstract][Full Text] [Related]
6. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
Sjoquist KM; Burmeister BH; Smithers BM; Zalcberg JR; Simes RJ; Barbour A; Gebski V;
Lancet Oncol; 2011 Jul; 12(7):681-92. PubMed ID: 21684205
[TBL] [Abstract][Full Text] [Related]
7. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
[TBL] [Abstract][Full Text] [Related]
8. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer.
Kranzfelder M; Schuster T; Geinitz H; Friess H; Büchler P
Br J Surg; 2011 Jun; 98(6):768-83. PubMed ID: 21462364
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
[TBL] [Abstract][Full Text] [Related]
11. The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients.
Yuan M; Bao Y; Ma Z; Men Y; Wang Y; Hui Z
Front Oncol; 2021; 11():628706. PubMed ID: 33777777
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma.
Mokdad AA; Minter RM; Yopp AC; Porembka MR; Wang SC; Zhu H; Augustine MM; Mansour JC; Choti MA; Polanco PM
J Natl Compr Canc Netw; 2018 Dec; 16(12):1468-1475. PubMed ID: 30545994
[No Abstract] [Full Text] [Related]
13. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.
Pasquali S; Yim G; Vohra RS; Mocellin S; Nyanhongo D; Marriott P; Geh JI; Griffiths EA
Ann Surg; 2017 Mar; 265(3):481-491. PubMed ID: 27429017
[TBL] [Abstract][Full Text] [Related]
14. Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies.
Tomasello G; Ghidini M; Ghidini A; Trevisan F; Celotti A; Russo A; Gambini D; Indini A; Rijavec E; Bareggi C; Galassi B; Petrelli F
Radiother Oncol; 2021 Nov; 164():13-19. PubMed ID: 34509562
[TBL] [Abstract][Full Text] [Related]
15. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review.
Liu W; Fu XL; Yang JY; Liu DJ; Li J; Zhang JF; Huo YM; Yang MW; Hua R; Sun YW
Medicine (Baltimore); 2016 Apr; 95(15):e3009. PubMed ID: 27082545
[TBL] [Abstract][Full Text] [Related]
17. Oncological outcomes of local excision compared with radical surgery after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis.
Shaikh I; Askari A; Ourû S; Warusavitarne J; Athanasiou T; Faiz O
Int J Colorectal Dis; 2015 Jan; 30(1):19-29. PubMed ID: 25367179
[TBL] [Abstract][Full Text] [Related]
18. The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis.
Yin S; Wang P; Xu X; Tan Y; Huang J; Xu H
J Cancer; 2019; 10(14):3094-3101. PubMed ID: 31289579
[No Abstract] [Full Text] [Related]
19. Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients: A Systematic Review and Meta-Analysis.
Lu H; Sun Y; Zhu Z; Yao J; Xu H; Huang R; Huang B
Ann Surg Oncol; 2022 Oct; 29(11):6962-6975. PubMed ID: 35723792
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol.
Lee JC; Ahn S; Paik KH; Kim HW; Kang J; Kim J; Hwang JH
BMJ Open; 2016 Mar; 6(3):e010491. PubMed ID: 27016245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
